Moderna Inc. (NASDAQ:MRNA) finished Thursday with an addition of $2.36 to close at $178.86, an upside of 1.34 percent. An average of 5,510,140 shares of common stock have been traded in the last five days. There was a fall of -$31.18 in the past week, and it reached a new high 2 times over the past 12 months. The last 20 days have seen an average of 7,551,920 shares traded, while the 50-day average volume stands at 5,741,362.
MRNA stock has increased by 3.30% in the last month. The company shares reached their 1-month lowest point of $162.78 on 12/12/22. With the stock rallying to its 52-week high on 01/03/22, shares of the company touched a low of $115.03 and a high of $259.20 in 52 weeks. It has reached a new high 1 time so far this year and lost -29.58% or -$75.12 in price. In spite of this, the price is down -31.00% from the 52-week high.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
MRNA stock investors should be aware that Moderna Inc. (MRNA) stock had its last reported insider trading activity 8 days ago on Dec 22. In this transaction, the insider spent $8,212,450. Chief Executive Officer, Bancel Stephane, disposed of 10,000 shares at a price of $209.82 on Dec 22. The insider now owns more than $2,098,200 worth of shares. Prior to that, Andres Juan went on to Sale 2,000 shares at $201.70 each on Dec 21. An amount of $403,400 was transacted.
Moderna Inc. (MRNA) has a trailing price-to-earnings (P/E) ratio of 6.47. The stock’s beta is 1.62. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 3.36, the price-to-book (PB) ratio at 3.88, and the price-to-cash flow ratio at 11.60.
The quick ratio of Moderna Inc. for the three months ended September 29 was 1.80, and the current ratio was 2.10, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.05 and a total debt to equity ratio of 0.06 for the quarter ending September 29. Its gross profit as reported stood at $15.85 billion compared to revenue of $18.47 billion.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Moderna Inc.’s return on assets was 45.10%.
For the three-month period that ended September 29, Moderna Inc. had $5.32 billion in cash. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of $1.04 billion in the quarter, while revenues of $2.2 billion were shrunk -219.56%. The analyst consensus anticipated Moderna Inc.’s latest quarter earnings to come in at $3.29 per share, but it turned out to be $2.53, a -23.10% surprise. For the quarter, EBITDA amounted to $1.28 billion. Shareholders own equity worth $384.18 million.
From a technical analysis perspective, let’s take a brief look at Moderna Inc. (MRNA) price momentum. RSI 9-day as of the close on 29 December was 42.32%, suggesting the stock is Neutral, with historical volatility in this time frame at 74.85%.
As of today, MRNA’s price is $188.59 -14.84% or -$31.18 from its 5-day moving average. MRNA is currently trading +1.68% higher than its 20-day SMA and -2.23% lower than its 100-day SMA. However, the stock’s current price level is +33.39% above the SMA50 and +20.75% above the SMA200.
The stochastic %K and %D were 28.88% and 41.73%, respectively, and the average true range (ATR) was 13.16. With the 14-day stochastic at 29.52% and the average true range at 12.59, the RSI (14) stands at 47.04%. The stock has reached -14.53 on the 9-day MACD Oscillator while the 14-day reading was at -13.89.
Jefferies upgraded Moderna Inc. (NASDAQ: MRNA) to a a Buy rating in its most recent analyst report. Previously, the stock was rated as a Hold.